The merger is fully financed with no financing condition, HSR clearance obtained, and ~27.4% of votes already committed. The key remaining condition is stockholder approval at the December 23 special meeting. Monitor for any stockholder litigation or appraisal demands that could delay closing, but the deal appears on track to close by end of Q4 2026.
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Lifecore Biomedical is being acquired by affiliates of Webster Equity Partners for $6.28 per share in cash plus one contingent value right (CVR) per share. The deal values the company at approximately $238 million in equity consideration (based on 37.9M common shares outstanding). The board unanimously recommends approval, and holders of ~27.4% of voting power have already agreed to vote in favor. The special meeting is scheduled for December 23, 2026.
Key Financial Metrics
Key Facts
- Merger consideration: $6.28 per share in cash plus one CVR per share
- Series A Preferred Stock holders receive Conversion Amount ($1,000/share + $18.125 accrued dividends as of Sept 27, 2026) plus CVRs
- Total funds needed at closing: approximately $550 million, funded by $400M equity commitment and $150M debt commitment ($115M term loans + $30M revolver + $35M Alcon term loan)
- HSR waiting period terminated early on November 4, 2026
- Voting and support agreements cover ~27.37% of combined voting power (Wynnefield and Legion stockholders)
- Company termination fee: $9,957,716 ($7,468,287 during go-shop period); Reverse termination fee: $16,181,288
- Board and Transaction Committee unanimously recommend FOR the merger
- Craig-Hallum delivered fairness opinion that the common stock merger consideration is fair from a financial point of view
- Appraisal rights available under Delaware law for dissenting stockholders
- Go-shop period ended October 28, 2026 with no acquisition proposal received
Financial Impact
Total equity consideration approximately $238M based on 37.9M common shares at $6.28/share, plus CVRs with milestone payments; total deal financing ~$550M
Risk Factors
- Failure to obtain stockholder approval (majority of combined voting power required)
- Stockholder appraisal demands could create uncertainty or delay
- CVR payments are contingent on future milestones and may be zero
- Alcon is both a major customer and a lender in the debt financing, creating potential conflicts
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFM14A Filing (Primary) | 0001140361-26-043742 |
| Document: ny20082863x2_defm14a.htm | 0001140361-26-043742 |
Track record
20 reports on LFCR
6 of 9 bullish or bearish reports moved the stock their way by T+1. Best: +45.27% at T+60 after the Mar 26, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $6.42 Now $6.42 +0.08% settles Nov 18
- Nov 13, 20263d ago DEFM14A Neutral 6/10 Viewing Entry $6.42 Now $6.42 +0.00% settles Nov 17
- Nov 5, 202611d ago 8-K / DEFA14A Neutral 5/10 Entry $6.40 to $6.36 Now $6.42 +0.31% ▼ −0.63% −0.94% vs SPY
- Nov 4, 202612d ago 8-K Bearish 6/10 No price data
- Nov 4, 202612d ago Press Release Bearish 5/10 Entry $6.44 to $6.40 Now $6.42 +0.31% ▲ +0.62% −3.79% vs SPY
- Oct 30, 202617d ago PREM14A Neutral 5/10 Entry $6.39 to $6.42 Now $6.42 +0.47% ▲ +0.47% +0.17% vs SPY
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $6.37 to $6.37 Now $6.42 +0.78% · 0.00% +1.18% vs SPY
- Sep 28, 20267w ago SC 13D/A Bullish 7/10 Entry $6.59 to $6.58 Now $6.42 −2.58% ▼ −0.15% +0.05% vs SPY
- Sep 28, 20267w ago DEFA14A Bullish 7/10 Entry $6.52 to $6.59 Now $6.42 −1.53% ▲ +1.07% +1.26% vs SPY
- Sep 28, 20267w ago 8-K Bullish 8/10 Entry $6.52 to $6.59 Now $6.42 −1.53% ▲ +1.07% +1.26% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers